Doctor of Osteopathy Program year 2021 Source: CMS Open Payments, 2026 publication

Robert Veland

Emergency Medicine Riverton, WY Doctor of Osteopathy

NPI 1720373111 CMS profile 350491

2100 W Sunset Dr, Riverton, WY 82501

Open in the dashboard

General payments

$393

18 records reported · program year 2021

Research payments

$0

Paid to them · None reported · program year 2021

Ownership & investment interest

$0

None reported

Through program year 2021, Robert Veland of Riverton, WY is reported in the CMS Open Payments database as having received $393 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2021 General $393 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Veland
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Robert Veland were reported at $0. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Robert Veland Emergency Medicine median Middle half National median
2019 $0 $51 $18–$128 $163
2020 $0 $29 $16–$99 $114
2021 $393 $40 $18–$124 $132
2022 $0 $49 $20–$134 $149
2023 $0 $51 $22–$142 $160
2024 $0 $52 $22–$150 $164
2025 $0 $57 $24–$150 $169

Breakdown

Who paid General payments · program year 2021
  1. AstraZeneca Pharmaceuticals LP $194 6 payments
  2. Biohaven Pharmaceuticals, Inc. $41 2 payments
  3. Amgen Inc. $28 2 payments
  4. GlaxoSmithKline, LLC. $27 2 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $22 1 payment
  6. Abbott Laboratories $20 1 payment
  7. Teva Pharmaceuticals USA, Inc. $18 1 payment
  8. Ultragenyx Pharmaceutical Inc. $16 1 payment
  9. Amarin Pharma Inc. $14 1 payment
  10. Sanofi-Aventis U.S. LLC $12 1 payment

Every payment, record by record

What the payments were for General payments · program year 2021
  1. Food and Beverage $393 18 payments
Products named General payments · program year 2021
  1. FARXIGA $163 4 payments
  2. NURTEC ODT $41 2 payments
  3. Otezla $28 2 payments
  4. AIMOVIG $28 2 payments
  5. Repatha $28 2 payments
  6. SHINGRIX $27 2 payments
  7. SYNJARDY $22 1 payment
  8. TRADJENTA $22 1 payment
  9. JARDIANCE $22 1 payment
  10. FreeStyle Libre 2 $20 1 payment
  11. Other $71 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

133

Median for Emergency Medicine: 88

Drug cost

$895

Median for Emergency Medicine: $590

Branded share of claims

61.7%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Odt Ondansetron Brand 22 $289
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 19 $232
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 26 $115
Cephalexin Generic 11 $77
Azithromycin Generic 15 $55
Ibuprofen Generic 13 $49
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $43
Prednisone Generic 12 $35

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$39,912

Medicare's payments for the services billed

Medicare patients

297

Average age 73

Services billed

401

174 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 42%
Diabetes 32%
Ischemic heart disease 27%
COPD 27%
Atrial fibrillation 25%
Depression 25%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record